| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
The Wellcome Research Laboratories, Research Triangle Park, North Carolina 27709
Acid-soluble extracts of bone marrow and blood samples from leukemia patients receiving 6-mercaptopurine were analyzed by anion-exchange high-pressure liquid chromatography. This has led to the identification of two previously unrecognized metabolites of 6-mercaptopurine, 6-methylmercaptopurine ribonucleoside 5'-diphosphate and the corresponding 5'-triphosphate. Intracellular concentrations of 6-methylmercaptopurine ribonucleoside 5'-triphosphate often exceeded those of either the corresponding 5'-mono- or 5'-diphosphate and were estimated to be as high as 145 µM. There is no evidence at present that these newly reported metabolites of 6-mercaptopurine are themselves highly cytotoxic, but they may perhaps contribute to the overall cytotoxicity of 6-mercaptopurine.
Received 8/13/73. Accepted 10/19/73.
This article has been cited by other articles:
![]() |
G. Zaza, M. Cheok, W. Yang, J. C. Panetta, C.-H. Pui, M. V. Relling, and W. E. Evans Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment Blood, September 1, 2005; 106(5): 1778 - 1785. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Dervieux, Y. Chu, Y. Su, C.-H. Pui, W. E. Evans, and M. V. Relling HPLC Determination of Thiopurine Nucleosides and Nucleotides in Vivo in Lymphoblasts following Mercaptopurine Therapy Clin. Chem., January 1, 2002; 48(1): 61 - 68. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |